ImmunityBio Inc Ordinary Shares IBRX 深 滬
等待開盤 11-15 09:30:00 美东时间
2.08
+0.080
+4.00%
華盛通- 最 高2.13
- 今 開1.97
- 成交量 717.32万股
- 最 低 1.95
- 昨 收 2.00
- 總市值 20.49亿
- 52周最高 5.43
- 市盈率 靜 --
- 換手率 0.73%
- 52周最低 1.83
- 委 比 -92.01%
- 總股本 9.85亿
- 歷史最高 45.42
- 量 比 0.88
- 振 幅 9.00%
- 歷史最低 0.93
- 每 手 1
- 風險率 0.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
HCW Biologics reported its third-quarter 2025 financial results and business highlights, including the planned Phase 1 clinical trial for HCW9302, a novel immunotherapy targeting autoimmune diseases, and the launch of a search for a commercial partner for its T-cell engager compounds. The company also highlighted the IND-enabling studies for HCW9302 and showcased data for its second-generation TCE and immune checkpoint inhibitor programs. Despite...
11-14 21:44
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
D. Boral Capital Maintains Buy on ImmunityBio, Maintains $24 Price Target
D. Boral Capital analyst Jason Kolbert maintains ImmunityBio (NASDAQ:IBRX) with a Buy and maintains $24 price target.
11-14 02:26
ImmunityBio Q3 EPS $(0.07) Beats $(0.10) Estimate, Sales $32.061M Beat $31.880M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.10) by 31.37 percent. This is a 50 percent increase over losses of $(0.14) per share from the same
11-05 14:48
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat.
10-23 01:42
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
美股大行评级 | 最高400美元！大行纷纷连夜上调甲骨文目标价；新思科技则惨遭多家大行下调目标价
今日重点评级关注：瑞银：上调Gossamer Bio评级至"买入"，目标价从1.25美元升至9美元；Canaccord Genuity：维持Corcept Therapeutics"买入"评级，目标价从137美元升至140美元
09-11 10:06
ImmunityBio Announces Paradigm Changing Findings From Phase 2 QUILT-3.055 Study, Showing ANKTIVA Reverses Lymphopenia In Patients With Checkpoint Inhibitor-Resistant Advanced NSCLC, With Reversal Resulting In Significant Prolonged mOS
Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lowers overall survival in non-small cell lung cancer and multiple types of cancer.1,2With
09-08 20:35
FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 28, 2025 /PRNewswire/ -- Federal budget cuts have put pressure on cancer research efforts in th...
08-28 22:44
What's Going On With ImmunityBio Shares Tuesday?
ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.
08-27 00:33
